Paul Stoffels, Group Chairman of Pharma R&D for Johnson & Johnson, authored an article on open innovation in the Feb. 2 issue of the Boston Globe in which he speaks about the trend and importance of open and collaborative models for innovation. Two things in particular impress me about this article:
- He articulates open innovation in clear and compelling language, spoken from someone who truly understands its value and has walked the talk... especially impressive coming from senior leadership at J&J
Also impressive since he's in an R&D function and obviously sees open innovation as a tool for increased leverage and productivity, and not as a threat as some R&D leaders do
Great read, so please check it out. Thanks to Check Frey at the excellent Innovation Tools for pointing me to this article.